Warning: The NCBI web site requires JavaScript to function. more...
Letrozole sensitizes breast cancer cells to ionizing radiation.
Azria D, Larbouret C, Cunat S, Ozsahin M, Gourgou S, Martineau P, Evans DB, Romieu G, Pujol P, Pèlegrin A.
Breast Cancer Res. 2005;7(1):R156-63. Epub 2004 Dec 7.
Related citations
The aromatase inhibitor letrozole and inhibitors of insulin-like growth factor I receptor synergistically induce apoptosis in in vitro models of estrogen-dependent breast cancer.
Lisztwan J, Pornon A, Chen B, Chen S, Evans DB.
Breast Cancer Res. 2008;10(4):R56. Epub 2008 Jul 8.
Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer.
Boulay A, Rudloff J, Ye J, Zumstein-Mecker S, O'Reilly T, Evans DB, Chen S, Lane HA.
Clin Cancer Res. 2005 Jul 15;11(14):5319-28.
Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial.
Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, Moscardo CL, Lemanski C, Coelho M, Rosenstein B, Fenoglietto P, Crompton NE, Ozsahin M.
Lancet Oncol. 2010 Mar;11(3):258-65. Epub 2010 Feb 6.
Effects of the antiestrogen tamoxifen and the aromatase inhibitor letrozole on serum hormones and bone characteristics in a preclinical tumor model for breast cancer.
Núñez NP, Jelovac D, Macedo L, Berrigan D, Perkins SN, Hursting SD, Barrett JC, Brodie A.
Clin Cancer Res. 2004 Aug 15;10(16):5375-80.
[Interactions between radiation and hormonal therapy in breast cancer: simultaneous or sequential treatment].
Fodor J.
Orv Hetil. 2006 Jan 22;147(3):121-5. Review. Hungarian.
Growth inhibition of estrogen receptor-positive and aromatase-positive human breast cancer cells in monolayer and spheroid cultures by letrozole, anastrozole, and tamoxifen.
Kijima I, Itoh T, Chen S.
J Steroid Biochem Mol Biol. 2005 Dec;97(4):360-8. Epub 2005 Nov 2.
Additive antitumor effect of aromatase inhibitor letrozole and antiestrogen fulvestrant in a postmenopausal breast cancer model.
Jelovac D, Macedo L, Goloubeva OG, Handratta V, Brodie AM.
Cancer Res. 2005 Jun 15;65(12):5439-44.
Effects of novel retinoic acid metabolism blocking agent (VN/14-1) on letrozole-insensitive breast cancer cells.
Belosay A, Brodie AM, Njar VC.
Cancer Res. 2006 Dec 1;66(23):11485-93.
Model systems: mechanisms involved in the loss of sensitivity to letrozole.
Brodie A, Jelovac D, Sabnis G, Long B, Macedo L, Goloubeva O.
J Steroid Biochem Mol Biol. 2005 May;95(1-5):41-8.
Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells.
Mitropoulou TN, Tzanakakis GN, Kletsas D, Kalofonos HP, Karamanos NK.
Int J Cancer. 2003 Mar 20;104(2):155-60.
Activation of mitogen-activated protein kinase in xenografts and cells during prolonged treatment with aromatase inhibitor letrozole.
Jelovac D, Sabnis G, Long BJ, Macedo L, Goloubeva OG, Brodie AM.
Cancer Res. 2005 Jun 15;65(12):5380-9.
Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth.
Patel JB, Mehta J, Belosay A, Sabnis G, Khandelwal A, Brodie AM, Soprano DR, Njar VC.
Br J Cancer. 2007 Apr 23;96(8):1204-15. Epub 2007 Mar 27.
Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole.
Macedo LF, Guo Z, Tilghman SL, Sabnis GJ, Qiu Y, Brodie A.
Cancer Res. 2006 Aug 1;66(15):7775-82.
Letrozole: a pharmacoeconomic review of its use in postmenopausal women with breast cancer.
Dunn C, Keam SJ.
Pharmacoeconomics. 2006;24(5):495-517. Review.
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.
Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
Heravi M, Rachid Z, Goudarzi A, Schlisser A, Jean-Claude BJ, Radzioch D, Muanza TM.
Anticancer Drugs. 2009 Sep;20(8):659-67.
Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M.
Clin Ther. 2007 Aug;29(8):1535-47. Review.
Xenograft models for aromatase inhibitor studies.
Brodie A, Sabnis G, Macedo L.
J Steroid Biochem Mol Biol. 2007 Aug-Sep;106(1-5):119-24. Epub 2007 May 24.
Letrozole-, anastrozole-, and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach.
Itoh T, Karlsberg K, Kijima I, Yuan YC, Smith D, Ye J, Chen S.
Mol Cancer Res. 2005 Apr;3(4):203-18.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on